Monday, January 17, 2022

Catching Up With MolDx: December Meeting on Rheumatoid Arthritis Therapy Selection

On December 7, 2021, MOLDX held a multi-jurisdictional advisory meeting on the topic, "Predictive Testing to Guide Targeted Therapy Selection in Rheumatoid Arthritis."

The webpage is here:

This is framed as a MolDx meeting, but many of the questions were directly on the drug therapies themselves (for example, different tolerance profiles of different TNF inhibitors), and only a few questions focused on targeted diagnostics.  The "PrismRA" test was mentioned a few times.  See the company EXAGEN in a recent Genomeweb article.

The questions, panel ratings of the questions, and transcript are posted online, as well as links to videos.  See link above or see the cut/paste below the break.

The transcript is worth reviewing for insights into the way MolDx medical directors think and the experts they were interviewing were focused and articulate.

Multi-Jurisdictional MolDX: Predictive Testing to 

Guide Targeted Therapy Selection in Rheumatoid Arthritis 

Contractor Advisory Committee (CAC): December 7, 2021

Palmetto GBA, CGS Administrators, Noridian Healthcare Solutions and WPS Government Health Administrators hosted a Multi-Jurisdictional Contractor Advisory Committee (CAC) Meeting via teleconference on December 7, 2021, from 2 to 4 p.m. ET. Discussions focused on MolDX: Predictive Testing to Guide Targeted Therapy Selection in Rheumatoid Arthritis. 

The Centers for Medicare and Medicaid Services (CMS) assigns Medicare Administrative Contractors (MACs) the task of developing Local Coverage Determinations (LCDs). The purpose of the CAC meeting is to provide a formal mechanism for healthcare professionals to be informed of the evidence used in developing the LCD and promote communications between the MAC and the healthcare community. The CAC panel discussed the clinical literature related to MolDX: Predictive Testing to Guide Targeted Therapy Selection in Rheumatoid Arthritis and rate their confidence in a series of key questions. Discussions occurred between CAC panelists and Contractor Medical Directors. The public was able to attend; however, questions from the public were not entertained. 

Meeting Materials